



Docket No.: PZ003P3
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ruben et al.

Application No.: 09/853,161

Confirmation No.:

Filed: May 11, 2001

Art Unit: 1647

For: Antibodies to Protein HPMBQ91 (As
Amended)

Examiner: R. B. Kapust

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 § CFR 1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AB-AI listed on the attached Form PTO/SB/08. A copy of each of references AB-AI is enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the reference(s) be made of record in the file history of the application.


Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this Second Supplemental Information Disclosure Statement if filed before the mailing date of a final Office Action under §1.113, a Notice of Allowance under §1.311, or an action that otherwise closes prosecution in this application and accompanied by the fee set forth in § 1.17(p). Accordingly, the required fee of \$180.00 is transmitted herewith with the concurrently filed Fee Transmittal.

Please charge our Deposit Account No. 08-3425 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 08-3425.

Dated: March 19, 2004

Respectfully submitted,

By


Janet M. Martineau

Registration No.: 46,903

HUMAN GENOME SCIENCES, INC.

14200 Shady Grove Road

Rockville, Maryland 20850

(301) 315-2723



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/853,161-Conf. #5950
Filing Date	May 11, 2001
First Named Inventor	Steven M. Ruben
Art Unit	1647
Examiner Name	R. B. Kapust
Attorney Docket Number	PZ003P3

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AB	WO-01/36979-A2	05-25-2001	University of Reading		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AC	KOTANI, H. et al., "Structure and gene organization of bovine neuromedin K precursor," Proc. Natl. Acad. Sci., USA, 83:7074-7078, (1986).	
	AD	KANGAWA, K. et al., "Neuromedin K: A Novel Mammalian Tachykinin Identified In Porcine Spinal Cord," Biochemical and Biophysical Research Communications, 114(2):533-540, ((1983).	
	AE	NAGASHIMA, A. et al., "Cardiovascular roles of tachykinin peptides in the nucleus tractus solitarii of rats," Brain Research, 487:392-396, (1989).	
	AF	ROCCON, A. et al., "Study of SR 14281, a new potent non-peptide NK ₃ receptor antagonist on cardiovascular responses in conscious guinea-pig," British Journal of Pharmacology, 118:1095-1102, (1996).	
	AG	BROWNBILL, P. et al., "Neurokinin B is a Paracrine Vasodilator in the Human Fetal Placental Circulation," Journal of Clinical Endocrinology and Metabolism, 88(5):2164-2170, (2003).	
	AH	PAGE, N.M. et al., "Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia," Nature, 405:797-800, (2000).	
	AI	Swiss-Prot entry Q9UHFO, "TKNK_HUMAN," (2001).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--